运用实时荧光定量RT-PCR检测人正常组织及肿瘤组织中BRDT表达

Determination of Expression Levels of BRDT in Normal and Cancer Tissues by Real-time Quantitative RT-PCR

目的探讨BRDT基因在正常组织及癌组织中的分布及其作为肿瘤治疗靶分子的可能性。方法运用实时荧光定量PCR方法分析BRDT在人正常组织及癌组织中的表达,使用18S rRNA作为内对照。结果在所检测的正常组织中该蛋白的mRNA只存在于睾丸组织中,而在其它组织不表达;在检测的10例胃腺癌组织标本中,有6例mRNA的微弱表达;在检测的10例食管鳞状细胞癌组织标本中,有3例mRNA的微弱表达;在检测的12例子宫颈鳞状细胞癌组织标本中均未有表达;在检测9例子宫内膜腺癌组织标本中,有2例微弱表达;在检测12例脑癌组织标本中,只有1例微弱表达。结论BRDT不可能作为子宫颈鳞状细胞癌、脑癌、子宫内膜腺癌及食管鳞状细胞癌治疗的潜在分子靶点,是否能够做胃腺癌的靶点还需进一步探讨。

Objective To study the distribution of BRDT(bromodomain testis specific gene product) gene in normal and cancer tissues, and explore whether BRDT can be used as a potential therapeutic target for cancer. Methods Analyze the expression of BRDT in normal and cancer tissues by real-time quantitative PCR, using 18S rRNA as an internal standard. Results No expression of BRDT mRNA were detected in normal tissues except testis. Low expressions were detected in 6 of 10 specimens of gastric adenocarcunoma tissue, 3 of 10 specimens of esophaged squamous cell carcinoma tissue, 2 of 9 specimens of endometrial carcinoma-tissue and 1 of 12 specimens of brain cancer tissue specimens. However, no expression was detected in 12 specimens of cervical squamous cell carcinoma tissue. Conclusion BRDT can not be used as a potential therapeutic target for cervical squeamous cell carcinoma, brain cancer, endometrial carcinoma or esophaged squamous cell carcinoma. Whether it can be used as a potential therapeutic target for gastric adenocarcunoma is to be further studied.